GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.» Read More
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
Employers have ratcheted up the financial incentives they offer workers to participate in wellness programs to a record this year.
Lower-income earners were much more likely to sign up for HealthCare.gov plans, higher earners were cooler to the Obamacare marketplace.
Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
Half of the households that received Obamacare subsidies will have to pay some of that money back, with an average repayment of nearly $800.
Angelina Jolie says she has had her ovaries and fallopian tubes removed to prevent cancer.
Hospitals have seen reductions in the costs of caring for the uninsured, but nowhere more so than in states that expanded Medicaid.
CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.
Anecdotal data suggests that many citizens appear to be opting to pay a fine rather than sign up for coverage under Obamacare, a report said.
Tenet and United Surgical Partners will combine their surgery centers in a deal that will give Tenet the option to buy USPI over the next five years.
Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.
Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.
The IRS announced that some Obamacare customers who received an incorrect form won't have to face amended returns.
A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.
Scientists have found a way to create mutant organisms more reliably using a recently developed gene-editing technique, NBC reports.
Want to know how many calories are in your shot of Johnnie Walker or your pint of Guinness? You're about to find out.
Federal authorities spent just $1 in probes for every $7.70 they recovered from health-care fraudsters, who remain a persistent, pricy problem.
As Biogen Idec gets set to reveal new data on its Alzheimer's drug, BIIB037, investors should be prepared for a big move either way.
What happens when a city tries to restrict fast food openings in poorer areas in hopes of reducing obesity?
Get the best of CNBC in your inbox